Drugs Monitor, Page 3

(13 May 2021) Losartan- no clinically significant impacts of ARB therapy in mildly hypoxemic patients

May 27, 2021

Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia https://doi.org/10.1007/s40121-021-00453-3 NCT04340557- Sixteen subjects received an ARB plus SOC and 15 subjects received SOC alone. The median age was… Continue reading "(13 May 2021) Losartan- no clinically significant impacts of ARB therapy in mildly hypoxemic patients"

(11 May 2021) Thymosin alpha1a- significantly shorter SARS-CoV-2 RNA shedding duration (13 vs. 16 days, p = 0.025)

May 27, 2021

Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching https://doi.org/10.3389/fmed.2021.664776 Among 1,388 enrolled patients, 232 patients (16.7%) received both Thymosin-alpha1 therapy and standard therapy (Thymosin-alpha1 group), and 1,156 patients… Continue reading "(11 May 2021) Thymosin alpha1a- significantly shorter SARS-CoV-2 RNA shedding duration (13 vs. 16 days, p = 0.025)"

(09 May 2021) Baricitinib- daily high dose of baricitinib in severe COVID-19 results in early stabilization of the respiratory functions

May 27, 2021

Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh https://doi.org/10.1186/s12879-021-06119-2 This prospective cohort study was conducted on 238 adult patients with severe COVID-19 pneumonia. Eight milligram and 4 mg of baricitinib was given… Continue reading "(09 May 2021) Baricitinib- daily high dose of baricitinib in severe COVID-19 results in early stabilization of the respiratory functions"

(06 May 2021) Ivermectin- the rate of clinical improvement was 73.3% Vs 53.3% in the control group

May 27, 2021

Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients https://doi.org/10.1186/s12879-021-06104-9 NCT04646109-A total of 66 patients, 36 in the study group and 30 in the control group were included in the study. Mutations affecting ivermectin… Continue reading "(06 May 2021) Ivermectin- the rate of clinical improvement was 73.3% Vs 53.3% in the control group"

(05 May 2021) Molnupiravir- was well tolerated at 400, 600 or 800mg doses with no severe adverse events

May 27, 2021

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study https://www.medrxiv.org/content/10.1101/2021.05.03.21256309v1 NCT04746183 – Of 103 volunteers screened, 18 participants were enrolled between 17 July and 30 October 2020. Molnupiravir was well tolerated… Continue reading "(05 May 2021) Molnupiravir- was well tolerated at 400, 600 or 800mg doses with no severe adverse events"

(04 May 2021) Hydroxychloroquine-neither stops disease progression nor helps in early and sustained viral clearance

May 27, 2021

Clearing the Fog: Is Hydroxychloroquine Effective in Reducing Coronavirus Disease-2019 Progression? A Randomized Controlled Trial https://doi.org/10.7759/cureus.14186 NCT04491994-A single-center open-label randomized controlled trial was conducted from April 10 to May 31, 2020 at Pak Emirates Military Hospital, Rawalpindi. Five hundred patients… Continue reading "(04 May 2021) Hydroxychloroquine-neither stops disease progression nor helps in early and sustained viral clearance"

(04 May 2021) Tocilizumab- early administration (IL-6 level < 100 pg/ml) may effectively improve the clinical prognosis

May 27, 2021

Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6 https://doi.org/10.3389/fmolb.2021.651662 This study aimed to evaluate the timing and efficacy of TCZ in the treatment of patients with COVID-19. A total of 58 consecutive patients who met… Continue reading "(04 May 2021) Tocilizumab- early administration (IL-6 level < 100 pg/ml) may effectively improve the clinical prognosis"

(04 May 2021) Lenzilumab- survival was improved by 2.17-fold

May 26, 2021

LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL https://www.medrxiv.org/content/10.1101/2021.05.01.21256470v1 NCT04351152- Subjects received steroids (93.7%), remdesivir (72.4%), or both (69.1%). Lenzilumab improved the likelihood of SWOV by 54% in the… Continue reading "(04 May 2021) Lenzilumab- survival was improved by 2.17-fold"

(03 May 2021) Tocilizumab- improved survival and other clinical outcomes

May 24, 2021

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial https://doi.org/10.1016/S0140-6736(21)00676-0 NCT04381936-Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment… Continue reading "(03 May 2021) Tocilizumab- improved survival and other clinical outcomes"

(03 May 2021) Baricitinib- when added to SOC, significantly decreased mortality

May 24, 2021

Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19 https://www.medrxiv.org/content/10.1101/2021.04.30.21255934v1 NCT04421027- In this phase 3, global, double-blind, randomized, placebo-controlled trial, 1525 hospitalized adults with COVID-19 receiving standard of care (SOC) were randomly assigned (1:1) to once-daily baricitinib 4-mg (N=764)… Continue reading "(03 May 2021) Baricitinib- when added to SOC, significantly decreased mortality"